At present, Prostate Specific Antigen (PSA) is still the core tumor marker used for diagnosing PCa in clinical practice, combined with Prostatic Acid Phosphatase (PAP) and Prostate Cancer Antigen 3(PCA3) for joint evaluation. The gene discussed is PCA3; the disease is posterior cortical atrophy.